申雅洁1,2 , 江代纪2 , 彭子京2 , 任逸倬2 , 齐以涛1,* , 马 皎2,*
1陕西师范大学生命科学学院细胞生物学系,西安 710119 2上海交通大学医学院生化及分子细胞生物学系,上海 200025

摘 要:


通讯作者:齐以涛 , 马 皎 ,

The advance in the role of SOX9 in tumorigenesis
SHEN Ya-Jie1,2 , JIANG Dai-Ji2 , PENG Zi-Jing2 , REN Yi-Zhuo2 , QI Yi-Tao1,* , MA Jiao2,*
1Department of Cell Biology, School of Life Science, Shaanxi Normal University, Xi’an 710062, China 2Department of Biochemistry and Molecular Cell Biology, School of Medicine, Shanghai Jiaotong University, Shanghai 200025, China


SRY-related high-mobility group box 9 (SOX9), as one member of the SOX family, is confirmed to be significantly involved in tumorigenesis. Nowadays, cancer treatment has been improved from traditional treatments like operation, radiotherapy and chemotherapy to the molecule-targeted treatment which targets the aberrant genes that are related to tumorigenesis. Therefore, it’s urgent to find new therapeutic targets for patients who are resistant to chemotherapy. Previous studies have demonstrated that SOX9 is closely related to tumor initiation, proliferation and migration because it can regulate multiple signaling pathways, such as Wnt signaling, Notch signaling etc, and diverse target genes. In this review, we first demonstrate the molecular structure and the physiological functions of SOX9. Next, we analyze the SOX9 expression profile in various human tumors in the Oncomine database. Finally, we summarize the molecular mechanisms underlying SOX9 pathological functions in various tumors. Ultimately, understanding the role of SOX9 in tumorigenesis will provide new insights into utilizing SOX9 as a potential therapeutic target for patients who developed acquired chemoresistance.

Communication Author:QI Yi-Tao , MA Jiao ,

Back to top